Defining field output factors in small fields based on dose area product measurements: A feasibility study.

BACKGROUND: Dose area product in water (DAPw) in small fields relies on the use of detectors with a sensitive area larger than the irradiation field. This quantity has recently been used to establish primary standards down to 5 mm field size, with an uncertainty smaller than 0.7%. It has the potential to decrease the uncertainty related to field output factors, but is not currently integrated into treatment planning systems. PURPOSE: This study aimed to explore the feasibility of converting DAPw into a point dose in small fields by determining the volume averaging correction factor. By determining the field output factors, a comparison between the so-called "DAPw to point dose" approach and the IAEA TRS483 methodology was performed. METHOD: Diodes, microdiamonds, and a micro ionization chamber were used to measure field output factors following the IAEA TRS483 methodology on two similar linacs equipped with circular cones down to 6 mm diameter. For the "DAPw to point dose" approach, measurements were performed with a dedicated and built-in-house 3 cm diameter plane-parallel ionization chamber calibrated in terms of DAPw in the French Primary Dosimetry Standards Laboratory LNE-LNHB. Beam profile measurements were performed to generate volume averaging correction factors enabling the conversion of an integral DAPw measurement into a point dose and the determination of the field output factors. Both sets of field output factors were compared. RESULTS: According to the IAEA TRS483 methodology, field output factors were within ±3% for all detectors on both linacs. Large variations were observed for the volume averaging correction factors with a maximum spread between the detectors of 26% for the smallest field size. Consequently, deviations of up to 15% between the "IAEA TRS483" and the "DAPw to point dose" methodologies were found for the field output factor of the smallest field size. This was attributed to the difficulty in accurately determining beam profiles in small fields. CONCLUSION: Although primary standards associated with small uncertainties can be established in terms of DAPw in a primary laboratory, the "DAPw to point dose" methodology requires volume averaging correction to derive a field output factor from DAPw measurements. None of the point detectors studied provided satisfactory results, and additional work using other detectors, such as film, is still required to allow the transfer of a DAP primary standard to users in terms of absorbed point dose.

Comparison of four synthetic CT generators for brain and prostate MR-only workflow in radiotherapy.

BACKGROUND: The interest in MR-only workflows is growing with the introduction of artificial intelligence in the synthetic CT generators converting MR images into CT images. The aim of this study was to evaluate several commercially available sCT generators for two anatomical localizations. METHODS: Four sCT generators were evaluated: one based on the bulk density method and three based on deep learning methods. The comparison was performed on large patient cohorts (brain: 42 patients and pelvis: 52 patients). It included geometric accuracy with the evaluation of Hounsfield Units (HU) mean error (ME) for several structures like the body, bones and soft tissues. Dose evaluation included metrics like the Dmean ME for bone structures (skull or femoral heads), PTV and soft tissues (brain or bladder or rectum). A 1%/1 mm gamma analysis was also performed. RESULTS: HU ME in the body were similar to those reported in the literature. Dmean ME were smaller than 2% for all structures. Mean gamma pass rate down to 78% were observed for the bulk density method in the brain. Performances of the bulk density generator were generally worse than the artificial intelligence generators for the brain but similar for the pelvis. None of the generators performed best in all the metrics studied. CONCLUSIONS: All four generators can be used in clinical practice to implement a MR-only workflow but the bulk density method clearly performed worst in the brain.

End-to-end quality assurance for stereotactic radiotherapy with Fricke-Xylenol orange-Gelatin gel dosimeter and dual-wavelength cone-beam optical CT readout.

PURPOSE: The end-to-end (E2E) quality assurance (QA) test is a unique tool for validating the treatment chain undergone by patients in external radiotherapy. It should be conducted in three dimensions (3D) to get accurate results. This study aims to implement these tests with Fricke-Xylenol orange-Gelatin (FXG) gel dosimeter and a newly developed dual-wavelength reading method on the Vista16™ optical Computed Tomography (CT) scanner (ModusQA) for three treatment techniques in stereotactic radiotherapy, on Novalis (Varian) and CyberKnife (Accuray) linear accelerators. METHODS: The tests were performed in head phantoms. Gel measurements were compared with planned dose distributions and measured by film and ion chamber measurements by plotting isodose curves and dose profiles, and by conducting a 3D local gamma-index analysis (2%/2mm criteria). RESULTS: Gamma passing rates were higher than 95 %. Point dose differences between treatment planning and gel and ion chamber measurements at the isocenter were < 2.3 % for both treatments delivered on the Novalis accelerator, while this difference was higher than 4 % for the treatment delivered on the CyberKnife, highlighting a small overdosing of the tumor volume. A good agreement was observed between gel and film dose profiles. CONCLUSIONS: This study presents the successful implementation of 3D E2E QA tests for stereotactic radiotherapy with FXG gel dosimetry and a dual-wavelength reading method on an optical CT scanner. This dosimetric method provides 3D absolute dose distributions in the 0.25 - 10 Gy dose range with a high spatial resolution and a dose uncertainty of around 2 % (k=1).

Dose area product primary standards established by graphite calorimetry at the LNE-LNHB for small radiation fields in radiotherapy.

PURPOSE: To present primary standards establishment in terms of Dose Area Product (DAP) for small field sizes. METHODS: A large section graphite calorimeter and two plane-parallel ionization chambers were designed and built in-house. These chambers were calibrated in a 6MV FFF beam at the maximum dose rate of 1400 UM/min for fields defined by specifically designed circular collimators of 5, 7.5, 10, 13 and 15 mm diameter and jaws of 5, 7, 10, 13 and 15 mm side length on a Varian TrueBeam linac. RESULTS: The two chambers show the same behaviour regardless of field shape and size. From 5 to 15 mm, calibration coefficients slightly increase with the field size with a magnitude of 1.8% and 1.1% respectively for the two chambers, and are independent of the field shape. This tendency was confirmed by Monte Carlo calculations. The average associated uncertainty of the calibration coefficients is around 0.6% at k=1. CONCLUSIONS: For the first time, primary standards in terms of DAP were established by graphite calorimetry for an extended range of small field sizes. These promising results open the door for an alternative approach in small fields dosimetry.

Lung stereotactic body radiation therapy: personalized PTV margins according to tumor location and number of four-dimensional CT scans.

OBJECTIVES: To characterise the motion of pulmonary tumours during stereotactic body radiation therapy (SBRT) and to evaluate different margins when creating the planning target volume (PTV) on a single 4D CT scan (4DCT). METHODS: We conducted a retrospective single-site analysis on 30 patients undergoing lung SBRT. Two 4DCTs (4DCT1 and 4DCT2) were performed on all patients. First, motion was recorded for each 4DCT in anterior-posterior (AP), superior-inferior (SI) and rightleft (RL) directions. Then, we used 3 different margins (3,4 and 5 mm) to create the PTV, from the internal target volume (ITV) of 4DCT1 only (PTV D1 + 3, PTV D1 + 4, PTV D1 + 5). We compared, using the Dice coefficient, the volumes of these 3 PTVs, to the PTV actually used for the treatment (PTVttt). Finally, new treatment plans were calculated using only these 3 PTVs. We studied the ratio of the D2%, D50% and D98% between each new plan and the plan actually used for the treatment (D2% PTVttt, D50% PTVttt, D50% ITVttt D98% PTVttt). RESULTS: 30 lesions were studied. The greatest motion was observed in the SI axis (8.8 ± 6.6 [0.4-25.8] mm). The Dice index was higher when comparing PTVttt to PTV D1 + 4 mm (0.89 ± 0.04 [0.82-0.98]). Large differences were observed when comparing plans relative to PTVttt and PTV D1 + 3 for D98% PTVttt (0.85 ± 0.24 [0.19-1.00]). and also for D98% ITVttt (0.93 ± 0.12 [0.4-1.0]).D98% PTVttt (0.85 ± 0.24 [0.19-1.00], p value = 0.003) was statistically different when comparing plans relative to PTVttt and PTV D1 + 3. No stastistically differences were observed when comparing plans relative to PTVttt and PTV D1 + 4. A difference greater than 10% relative to D98% PTVttt was found for only in one UL lesion, located under the carina. CONCLUSION: A single 4DCT appears feasible for upper lobe lesions located above the carina, using a 4-mm margin to generate the PTV. ADVANCE IN KNOWLEDGE: Propostion of a personalized SBRT treatment (number of 4DCT, margins) according to tumor location (above or under the carina).

A Bayesian control chart based on the beta distribution for monitoring the two-dimensional gamma index pass rate in the context of patient-specific quality assurance.

PURPOSE: In the context of quality assurance in intensity modulated radiation therapy (IMRT), the aim of this work was two-fold: (a) to show that the beta distribution characterizes the two-dimensional gamma index pass rate (GIPR), and that the quantiles of the distribution should be used in order to compute the control limit (CL) for the detection of abnormally low GIPR, and (b) to introduce a Bayesian control chart that allows calculation of CLs from the first measurement. METHODS: In order to enable monitoring of the GIPR from the first measurement, we developed a Bayesian control chart based on the beta distribution, elaborated according to the following two steps: (a) an iterative bayesian inference approach without any prior information on the GIPR distribution was used at the start of monitoring and the CL was progressively updated; and (b) when sufficient in-control arcs had been recorded and the estimators of the parameters of the beta distribution were sufficiently accurate, the CL of the chart was fixed to a constant value corresponding to the quantile of the beta distribution. The clinical utility of this approach is illustrated through a real data case study: monitoring the GIPR of patients treated with a moving gantry IMRT technique RapidArcTM on a Novalis TrueBeam STx (Varian Medical Systems) linear accelerator equipped with an aS1200 electronic portal imager device. RESULTS: We showed that some commonly used distributions for monitoring GIPR in the literature, such as normal or logarithm transformation, are not appropriate. We compared the CLs of those solutions with the CL of our chart based on the BD (CL = 95.14%). The comparison revealed that the CL for the normal law (CL = 97.62%) generated too many false positives, and that the CL of the Logarithm transformation (CL = 83.74%) could fail to efficiently detect (i.e., sufficiently early on or faster) changes in the process. CONCLUSIONS: Successful GIPR monitoring requires careful and rigorous application of well-established statistical concepts in the field of statistical process control. In this paper, we stress the importance of carefully analyzing the distribution of the monitored characteristic that is plotted on the control chart. We propose a Bayesian control chart that can be viewed as a practical solution for early implementation of GIPR monitoring, starting from the first arc. We demonstrate that beta distribution is a better method for characterizing the GIPR, and thus, the use of this approach is expected to improve patient-specific quality assurance plans in radiotherapy.

Feasibility of using a dose-area product ratio as beam quality specifier for photon beams with small field sizes.

PURPOSE: To investigate the feasibility of using the ratio of dose-area product at 20 cm and 10 cm water depths (DAPR20,10) as a beam quality specifier for radiotherapy photon beams with field diameter below 2 cm. METHODS: Dose-area product was determined as the integral of absorbed dose to water (Dw) over a surface larger than the beam size. 6 MV and 10 MV photon beams with field diameters from 0.75 cm to 2 cm were considered. Monte Carlo (MC) simulations were performed to calculate energy-dependent dosimetric parameters and to study the DAPR20,10 properties. Aspects relevant to DAPR20,10 measurement were explored using large-area plane-parallel ionization chambers with different diameters. RESULTS: DAPR20,10 was nearly independent of field size in line with the small differences among the corresponding mean beam energies. Both MC and experimental results showed a dependence of DAPR20,10 on the measurement setup and the surface over which Dw is integrated. For a given setup, DAPR20,10 values obtained using ionization chambers with different air-cavity diameters agreed with one another within 0.4%, after the application of MC correction factors accounting for effects due to the chamber size. DAPR20,10 differences among the small field sizes were within 1% and sensitivity to the beam energy resulted similar to that of established beam quality specifiers based on the point measurement of Dw. CONCLUSIONS: For a specific measurement setup and integration area, DAPR20,10 proved suitable to specify the beam quality of small photon beams for the selection of energy-dependent dosimetric parameters.